Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Region Västmanland | OTHER |
Not provided
Not provided
Not provided
Not provided
This observational study aims to evaluate risk factors of progress and adverse outcome of aortic regurgitation
Aortic regurgitation is relatively common, with a prevalence of 13% for men and 8,5% for women in the Framingham study (Singh et al). Patients with aortic regurgitation are evaluated regularly with echocardiography to see if progress occurs, and suitable candidates are referred for surgical repair or replacement of the aortic valve.
However, an American study from 2019 showed that only 12% of cases of aortic regurgitation progressed from mild to moderate or severe over a 10 years period (Yang et al). This means that the majority of patients undergo echocardiographic evaluations without a clinical benefit.
It is unclear whether these findings also apply to a Swedish population with the European definitions for aortic regurgitation.
Aim:
To do a retrospective analysis of patients evaluated with echocardiography in Västerås, Sweden between January 2003 and March 2025 to describe the prevalence of aortic regurgitation as well as aortic dilatation, to describe how often progress occurs in patients with mild or moderate aortic regurgitation, and finally to look at factors (clinical, echocardiographic) associated with progress of aortic regurgitation as well as outcome (mortality, MACE, cardiac surgery).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with aortic regurgitation | Observational study, no interventions |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Progress of aortic regurgitation | Progress of aortic regurgitation from mild to moderate or severe, or moderate to severe. Progress is defined according to current European Society for Cardiology guidelines using a comprehensive echocardiographic assessment | Depending on when the patients was evaluated first, up to approximately 20 years of follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Surgical treatment of aortic regurgitation or aortic aneurysm | Surgical treatment of aortic regurgitation or aortic aneurysm | Depending on when the patients was evaluated first, up to approximately 20 years of follow-up |
| Hospitalization for heart failure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Adult patients with aortic regurgitation
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Matthijs Velders, MD PhD | Contact | +4621-175947 | matthijs.velders@regionvastmanland.se |
| Name | Affiliation | Role |
|---|---|---|
| Matthijs Velders, MD PhD | Region Västmanland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Västmanlands sjukhus Västerås | Västerås | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31727286 | Background | Yang LT, Enriquez-Sarano M, Michelena HI, Nkomo VT, Scott CG, Bailey KR, Oguz D, Wajih Ullah M, Pellikka PA. Predictors of Progression in Patients With Stage B Aortic Regurgitation. J Am Coll Cardiol. 2019 Nov 19;74(20):2480-2492. doi: 10.1016/j.jacc.2019.08.1058. | |
| 10190406 | Background | Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999 Mar 15;83(6):897-902. doi: 10.1016/s0002-9149(98)01064-9. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001022 | Aortic Valve Insufficiency |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Hospitalization for heart failure during follow-up |
| Depending on when the patients was evaluated first, up to approximately 20 years of follow-up |
| Hospitalization for stroke or myocardial infarction | Composite endpoint | Depending on when the patients was evaluated first, up to approximately 20 years of follow-up |
| All-cause mortality | All-cause mortality during follow-up | Depending on when the patients was evaluated first, up to approximately 20 years of follow-up |